Neurological disorders Archives

News and Trends 15 Oct 2015

Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

Minoryx Therapeutics is a Barcelona based Rare-disease specialist who has a panel of orphan-drug experts for their discovery program. Now backed in a €19.4M Series A round from leading VC firms Ysios (No 15 in our top EU VCs) and Roche Venture Fund, Minoryx will have the well-needed cash to push for further R&D of their […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

High-Risk Infant Cancer: Nature publishes on a New and Reliable Biomarker from Cologne

New Oncology from Cologne (Germany) is a biotech which today published a paper in Nature on tumor-profile recognition of cancer of the sympathetic nervous system (Neuroblastoma) in conjunction with the latest research at the University of Cologne. The research team has found a new way to diagnose infants with the deadly high-risk version of Neuroblastoma, which […]

October 14, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 9 Oct 2015

TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough

The Tau protein has already been implicated in the onset of Alzheimer’s, with many biotechs on the hunt for a preventative therapy. Now, a University of Aberdeen (UK) associated biotech, TauRX, have drawn €120M for their phase III therapy. TauRX is a spin-off biotech from the University of Aberdeen in Scotland (UK) where its clinical […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 1 Oct 2015

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Paris based Sofinnova continues to invest in the Alzheimer’s fight, with a €27.5M pot given to Swiss Asceneuron (originally a spin-off from Merck-Serono). Sofinnova therefore joins other investors such as JJDC in the new and optimistic biotech wave of therapies for neurodegenerative diseases like Alzheimer’s and progressive supranuclear palsy (PSP). The last decade has been fairly […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 28 Sep 2015

New Smart Collaboration of Nestlé and AC Immune Against Alzheimer’s disease

Nestlé Institute of Health Sciences (NIHS) is teaming up with the Swiss AC Immune to develop a new minimally invasive Tau diagnostic assay for early diagnosis of Alzheimer’s disease. Alzheimer’s disease has a new case every three seconds, totaling up to 9.9 million new cases of dementia every year. To combat this, AC Immune will […]

September 28, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 22 Sep 2015

UniQure’s cure for rare Lysosomal disease ready for phase III trial

UniQure from the Netherlands has promising results for its enzyme replacement therapy phase Ib/II trial targeting a rare Lysosomal disease. This has granted fast-track approval to launch its phase III trial for children with Sanfilippo Type B (MPS-III) in collaboration with France’s Institut Pasteur. UniQure is the Amsterdam gene-therapy biotech with a lot going on. Last year […]

September 22, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 17 Jul 2015

AC Immune receives Milestone Payment for Alzheimer Antibody

AC Immune received a first milestone payment from Roche’s subsidiary Genentech. The latter picked up a potential Alzheimer’s drug worth developing towards clinical trials. The collaboration began in 2012 with Genentech’s promising milestone payments amounting to more than €384M (CHF400M). Alzheimer’s disease will be one of the biggest burdens of tomorrow’s society showing a dramaticaly […]

July 17, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Jul 2015

After being rejected twice, Horizon pushes Depomed to accept its €2.7Bn offer

Horizon Pharma is getting anxious and has offered the substantial amount of €2.7Bn to buy its American competitor Depomed. The Irish drug-maker plans to add the US-based firm to its shopping list just after enrolling Hyperion Therapeutics, the company that was purchased only one month ago. Dublin-based Horizon has been pursuing Depomed lately, but the American company is playing […]

July 13, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 10 Jul 2015

First-in-human successful Phase I for an Alzheimer’s vaccine

AXON Neuroscience has completed a pioneer Phase I that offers new hope for millions of patients with Alzheimer’s disease. This makes AXON the first company to successfully complete this clinical trial for a vaccine that targets diseased tau proteins, which cause neural degeneration. Alzheimer’s disease is characterized by the presence of prejudicial forms of protein […]

July 10, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jul 2015

Roche and Evotec knocked down by their Alzheimer candidate

The progressive aging of the population in developed countries is turning Alzheimer into one of the biggest medical challenges of our times. And it looks like it is going to remain an unresolved problem for the moment, as Roche’s candidate failed its last clinical trial. The drug, developed in collaboration with German Evotec, didn’t meet […]

July 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Mar 2015

Alkermes presents its new treatment of Alzheimer’s agitation

Alkermes reveals a new drug candidate, ALKS 7119, for treatment of Alzheimer’s agitation, depression and other central nervous system (CNS) diseases. Alkermes has successfully completed preclinical development and expects to initiate the first clinical study of its newest candidate, ALKS 7119, in the third quarter of 2015. ALKS 7119 has a multivalent mechanism of action […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 Feb 2015

#BioFigures: 3,000 whole genomes sequenced to fight Parkinson!

WHO? 23andMe, founded in 2006, is the leading personal genetics company dedicated to helping people access, understand and benefit from the human genome. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research. Photo credit: 23andMe WHAT? 23andMe, announced an agreement with Genentech, a member of the Swiss Roche Group, […]

February 18, 2015 - 2 minutesmins - By Marie Godar

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurological disorders

Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

High-Risk Infant Cancer: Nature publishes on a New and Reliable Biomarker from Cologne

TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

New Smart Collaboration of Nestlé and AC Immune Against Alzheimer’s disease

UniQure’s cure for rare Lysosomal disease ready for phase III trial

AC Immune receives Milestone Payment for Alzheimer Antibody

After being rejected twice, Horizon pushes Depomed to accept its €2.7Bn offer

First-in-human successful Phase I for an Alzheimer’s vaccine

Roche and Evotec knocked down by their Alzheimer candidate

Alkermes presents its new treatment of Alzheimer’s agitation

#BioFigures: 3,000 whole genomes sequenced to fight Parkinson!

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!